IBM Is Turning Into Red Hat on Steroids

IBM Is Turning Into Red Hat on Steroids

With every passing quarter, IBM (NYSE: IBM) looks more and more like an amped-up version of Red Hat. After buying the open-source software veteran in a blockbuster $40 billion deal in 2019, Big Blue has only increased its focus on exactly the things Red Hat did best when it was a separate company.